S95024 / Servier - LARVOL DELTA

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Symphogen A/S | Active, not recruiting ➔ Completed

Combination therapy • Metastases • Monotherapy • Trial completion • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MSI

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Symphogen A/S | N=100 ➔ 48

Combination therapy • Enrollment change • Metastases • Monotherapy • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MSI

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=100 | Active, not recruiting | Sponsor: Symphogen A/S | Trial completion date: Jul 2024 ➔ Dec 2024 | Trial primary completion date: Jul 2024 ➔ Dec 2024

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MSI

Molecular and early clinical characterization of the anti-CD73 antibody S095024 (Sym024) (AACR 2024) - P1 | "The clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of S095024 alone or in combination with Sym021, an anti-PD1 antibody, was investigated in a first-in-human study (NCT04672434) in patients with selected types of advanced solid tumors. These findings reveal the potential of S095024 (Sym024) to prevent adenosine-mediated tumor evasion and support further clinical investigation."

Clinical • IO biomarker • Oncology • Solid Tumor • CD73 • ENTPD1 • NT5E

Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D (PRNewswire) - P1 | N=100 | NCT04672434 | "Research to be presented includes biomarker data from a phase 1 dose escalation study of the anti-CD73 antibody (S095024, Sym024) alone or in combination with anti-PD-1. The data illustrates dose dependent target engagement in the tumor and reveals the potential of anti-CD73 to prevent adenosine-mediated tumor evasion."

P1 data • Oncology • Solid Tumor

Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D (PRNewswire) - P1 | N=100 | NCT04672434 | Sponsor: Symphogen A/S | "Servier...is poised to unveil promising preliminary data at the American Association for Cancer Research (AACR) Annual Meeting 2024....Research to be presented includes biomarker data from a phase 1 dose escalation study of the anti-CD73 antibody (S095024, Sym024) alone or in combination with anti-PD-1. The data illustrates dose dependent target engagement in the tumor and reveals the potential of anti-CD73 to prevent adenosine-mediated tumor evasion."

Biomarker • P1 data • Oncology • Solid Tumor

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=100 | Active, not recruiting | Sponsor: Symphogen A/S | Trial completion date: Dec 2023 ➔ Jul 2024 | Trial primary completion date: Dec 2023 ➔ Jul 2024

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MSI

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=100 | Active, not recruiting | Sponsor: Symphogen A/S | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Metastases • Monotherapy • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MSI

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Symphogen A/S | Trial completion date: Jun 2024 ➔ Dec 2023 | Trial primary completion date: Jun 2024 ➔ Dec 2023

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MSI

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Symphogen A/S | Trial completion date: Mar 2024 ➔ Jun 2024 | Trial primary completion date: Mar 2024 ➔ Jun 2024

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • MSI

[VIRTUAL] Preclinical characterization of Sym024, a novel anti-CD73 antibody (AACR 2021) - "In vitro one-way mixed lymphocyte reaction results demonstrate the utility of combining CD73 inhibition with PD-1 blockade, as Sym024 acts to reverse the immune suppressive effect of adenosine production, thereby allowing effective T cell activation by an anti-PD-1 antibody (Sym021). Dose-proportional and linear pharmacokinetics (PK) was observed at high dose levels while nonlinear PK became evident at lower exposure levels. Sym024 is currently under clinical investigation."

IO biomarker • Preclinical • Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • CD4 • CD73 • CD8 • ENTPD1 • NT5E

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1; N=100; Recruiting; Sponsor: Symphogen A/S

Clinical • Combination therapy • Monotherapy • New P1 trial • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck